DOYLE MITTIE (Chief Medical Officer) sold 45.3% of their position (3K shares) of AVALO THERAPEUTICS, INC. on the open market
Open‑market sale worth $56.3K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 5/19/2026ACC: 0001918845-26-000012
Officer· Chief Medical Officer
Since Feb 2026
-3K
Net shares
Net seller
$56.3K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
3K acquired · 6K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+3K
Price / share
$12.65
Trade value
$37.95K
% of position
82.8%
5/15/2026
3.62K→6.62K
Common Stock
Direct
Shares
−3K
Price / share
$18.76
Trade value
$56.28K
% of position
45.3%
5/15/2026
6.62K→3.62K
Total
Net shares
+0.00
Net value
-$18.33K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/15/2026 | M · Option Exercise | +3K | $12.65 | $37.95K | 82.8% | 3.62K | 6.62K |
| Common Stock Direct | 5/15/2026 | S · Sale | −3K | $18.76 | $56.28K | 45.3% | 6.62K | 3.62K |
| Total | +0.00 | -$18.33K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
3K shares
Shares
−3K
Strike price
12.65
Held after
128.63K
Exercisable
—
5/15/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock3K shares | 5/15/2026 | M · Option Exercise | −3K | 12.65 | — | 128.63K |